Cargando…
Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid
The programmed cell death protein 1 inhibitor pembrolizumab, an immune checkpoint inhibitor, has subsequently been approved for the treatment of a wide variety of malignant tumors. Compared with conventional chemotherapy, immunotherapy is associated with a unique set of immune reactions, known colle...
Autores principales: | Zhang, Xiaoyan, Sui, Dongjiang, Wang, Dong, Zhang, Lina, Wang, Ruiyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477373/ https://www.ncbi.nlm.nih.gov/pubmed/34594337 http://dx.doi.org/10.3389/fimmu.2021.731774 |
Ejemplares similares
-
Pembrolizumab-induced bullous pemphigoid
por: Sun, Christina W., et al.
Publicado: (2019) -
Dupilumab for the treatment of pembrolizumab‐induced bullous pemphigoid: A case report
por: Pop, Samantha R., et al.
Publicado: (2022) -
Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports
por: Thomsen, Kenneth, et al.
Publicado: (2018) -
Case Report: The many faces of bullous pemphigoid
por: Rechtien, Laura, et al.
Publicado: (2023) -
Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid
por: Wang, Jianglin, et al.
Publicado: (2023)